2024-01-11 17:18:11
1704995074
#Assassinations #negotiations.. #Israel #reach #Nasrallah #Sky #News #Arabia
Category:
Trump’s ex-wife responds to her cheating on him with a famous artist… Will she vote for him in the upcoming elections? (video)
written by Alexandra Hartman Editor-in-Chief
2024-01-11 15:18:00
Marla Maples has denied cheating on Donald Trump with Michael Bolton while they were married, saying she dated the singer but was “always faithful” to her ex-husband.
Trump’s mistress, who became his second wife, spoke regarding her love triangle before leaving Los Angeles International Airport on Tuesday, hinting that her ex-husband would get “her vote” in the upcoming 2024 elections.
In detail, Maples, 60, was wearing a gray sweater, jeans, and white sneakers while she was waiting in line to check her luggage.
With coffee in hand, she was heading to security when she met a photographer who asked her regarding her relationship with Bolton, now 70, in the 1990s.
The photographer pointed to old FBI files that claimed she had an affair with singer Michael Bolton while she was married to Trump, now 77, her first and only husband.
In turn, Bolton revealed last week that he had been diagnosed with brain cancer before the holidays, which required him to undergo “immediate surgery,” which was “successful.”
1704994816
#Trumps #exwife #responds #cheating #famous #artist.. #vote #upcoming #elections #video
2024-01-11 17:00:00
Thermo Fisher to produce for Galapagos
The Dutch biotech has signed with Thermo Fisher for the production of its CAR-T drug candidate, which will be carried out in the San Francisco region (United States). Thermo Fisher will also be in charge of services associated with treatment such as logistics for this clinical program positioned in oncohematology. In November 2023, Galapagos had entrusted Landmark Bio with the manufacturing of its CAR-T for the Eastern United States, in Boston. A decentralized production network essential to progress on clinical trials and possible arrival of the treatment on the market.
Novartis joins SanReno
The Swiss laboratory got its hands on SanReno Therapeutics, a Chinese biotech specializing in treatments for kidney diseases. SanReno has rights in Greater China and Singapore to two late-stage products targeting immunoglobulin A nephropathy, or Berger’s disease. Atrasentan, an oral treatment, has already met its primary endpoint in phase III
while zigakibart, a subcutaneous monoclonal antibody, was authorized to begin phase III last October. Financial details of the operation have not been disclosed.
I will tell you
source
Iktos to work with Nerviano Medical Sciences
The French startup, specializing in AI for the design of new drugs, has just entered into a collaboration with the Italian biotech Nerviano Medical Sciences, positioned in oncology. The agreement will focus on kinases with the aim of identifying at least one promising molecule. Iktoswhich raised €15.50 million in May 2023, is increasing its collaborations in pharma with Kissei Pharmaceutical and Galapagos in particular.
Inventiva refinances to the tune of €25 million
The French biotech, specializing in NASH, announced the drawing of the second tranche, amounting to 25 million euros, of the loan granted by the EIB in May 2022. An operation made possible by the achievement of key milestones by Inventiveness. This drawdown will make it possible to continue financing its pivotal phase III clinical study evaluating lanifibranor once morest NASH, the results of which are planned to be published in the first half of 2026. With this financing, Inventiva ensures financial visibility until start of the third quarter of 2024.
CDMO: WuXi boosts its peptide manufacturing capacity
The Chinese CDMO Wuxi, through its WuXi AppTec division, is preparing to commission two new peptide manufacturing plants in China, in Changzhou and Taixing. In Changzhou, this is the manufacturer’s third dedicated peptide facility. In Taixing, the site is expected to be fully operational by 2025. With these investments, WuXi AppTec now has five API production sites, with solid-phase peptide synthesis capacity at 32,000 liters. “Our increased capacity is essential to accelerate drug development and ensure a reliable supply chain for our global partners”, said Minzhang Chen, CEO of WuXi AppTec. As of 2023, WuXi has supported approximately fifty peptide-focused projects, ranging from preclinical to commercial, and produced fifteen tons of peptide APIs and intermediates.
Selected for you
1704994601
#Galapagos #Novartis #Iktos #Inventiva #Wuxi
completion of the operation to reduce the number of subsidiary companies
written by Alexandra Hartman Editor-in-Chief
2024-01-11 16:36:54
ALGIERS – The Sonelgaz group announced, Thursday in a press release, having completed the operation to reduce the number of subsidiary companies, from 34 to 11 companies, following the merger-absorption of three subsidiary companies.
As part of the final phase of the operation to reduce the number of subsidiary companies of the group, this involves the merger-absorption by the company Sonelgaz-Production of electricity of the company Shariket Kahraba El Djazair (SKE) , the merger-absorption by the company Sonelgaz-Renewable Energies of the Algerian company of renewable energies (Shaems) and the merger-absorption by the company Sonelgaz-services of the company Shariket Amn Wa Himayat El Mounchaat El Kahrabaiya Wa El Ghaziya, specifies the same source.
This operation comes following the conclusions of the meeting of the board of directors held on Wednesday and follows the reorganization and restructuring process undertaken by Sonelgaz since 2022, having made it possible to “rejuvenate the management of its companies in a fluid and progressive manner, while by preserving all the socio-professional achievements of its staff and giving them new opportunities for development and advancement of their careers,” notes the press release.
On this occasion, the CEO of Sonelgaz, Mourad Adjal chaired a ceremony in the presence of representatives of workers’ unions and participation committees as well as executives of the group, during which he proceeded with the installation of new management executives of the companies Sonelgaz-distribution, Sonelgaz-electricity transmission and system operator, Sonelgaz-renewable energies, Sonelgaz-engineering and Sonlegaz-services, in addition to the installation of several senior executives in the Holding company.
The CEO of Sonelgaz praised “the efforts made by the social partner to ensure the stability of the working climate within the group’s companies”, expressing his thanks to all of the company’s workers for the achievements recorded in over the last two years, particularly with regard to the implementation of the development programs of the President of the Republic, Mr. Abdelmadjid Tebboune, including energy connection projects for remote areas, agricultural farms and industrial zones,” adds the same source.
1704994517
#completion #operation #reduce #number #subsidiary #companies